Physician profile
Nicholas J Procaccini
NPI 1336351147
$4,124.33
in general payments reported to CMS, 2019-2025
26 companies · $1,968 in 2025
The $1,968 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.62 · 2020: $38.12 · 2023: $56.27 · 2024: $1,964 · 2025: $1,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,939 · Education: $49.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,939.38 |
| Education | $49.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,229.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $608.30 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $453.70 | 2023-2025 | Tremfya, Stelara |
| Pfizer INC. | $267.51 | 2024-2025 | |
| Madrigal Pharmaceuticals | $210.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $206.77 | 2024-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $174.90 | 2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $158.22 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $146.42 | 2024-2025 | Vowst, Zenpep |
| Merck Sharp & Dohme LLC | $92.89 | 2024 | Dificid, Prevymis |
| Gilead Sciences, INC. | $90.78 | 2019-2024 | |
| Celltrion USA INC. | $74.59 | 2024-2025 | Zymfentra, Vegzelma |
| Lilly USA, LLC | $71.02 | 2023-2025 | Omvoh |
| Genzyme Corporation | $59.88 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.68 | 2024-2025 | Trulance, Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $45.65 | 2024-2025 | Sucraid, Sucraid |
| Celgene Corporation | $36.05 | 2024 | Zeposia |
| Organon LLC | $32.41 | 2024 | |
| Daiichi Sankyo INC. | $29.47 | 2025 | Injectafer |
| Orphalan INC | $29.39 | 2025 | Cuvrior |
| Recordati_rare_diseases_inc. | $21.52 | 2025 | Panhematin |
| Intercept Pharmaceuticals, INC. | $16.89 | 2025 | |
| Digestive Care, INC. | $12.13 | 2025 | Pertzye |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Procaccini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.